Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics ($HALO), sold about $1.7 million in company shares across four open market transactions over the past year. Her most recent sale occurred on September 22, 2025. These sales rank her 3,821st among 11,678 insiders in our database by total value sold, below the average of $8.6 million per insider and 6.4 transactions. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Performance Stock Units | 6688 | $0.00 | 36,357.0000 | 123,904,000 | 15.54% | 0.01% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 5332 | $0.00 | 38,290.0000 | 123,904,000 | 16.18% | 0.00% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 2876 | $70.98 | 35,414.0000 | 123,904,000 | 7.51% | 0.00% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 6688 | $0.00 | 42,102.0000 | 123,904,000 | 18.89% | 0.01% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 3608 | $70.64 | 38,494.0000 | 123,904,000 | 8.57% | 0.00% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 5332 | $0.00 | 15,995.0000 | 123,904,000 | 25.00% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 5093 | $0.00 | 27,172.0000 | 123,904,000 | 23.07% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Performance Stock Units | 13351 | $0.00 | 0.0000 | 123,904,000 | 100.00% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 5329 | $0.00 | 5,329.0000 | 123,904,000 | 50.00% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 5093 | $0.00 | 0.0000 | 123,904,000 | 100.00% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 7273 | $79.44 | 32,958.0000 | 123,904,000 | 18.08% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 13351 | $0.00 | 40,231.0000 | 123,904,000 | 49.67% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 2874 | $79.44 | 26,880.0000 | 123,904,000 | 9.66% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 5329 | $0.00 | 29,754.0000 | 123,904,000 | 21.82% | 0.00% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 2747 | $79.44 | 24,425.0000 | 123,904,000 | 10.11% | 0.00% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Performance Stock Units | 7448 | $0.00 | 43,045.0000 | 123,904,000 | 20.92% | 0.01% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Performance Stock Units | 29502 | $0.00 | 29,502.0000 | 123,904,000 | 9999.99% | 0.02% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Performance Stock Units | 5167 | $0.00 | 13,351.0000 | 123,904,000 | 63.14% | 0.00% |
| Sept. 22, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 1913 | $77.83 | 22,393.0000 | 129,424,000 | 7.87% | 0.00% |
| Sept. 22, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 314 | $78.67 | 22,079.0000 | 129,424,000 | 1.40% | 0.00% |
| Sept. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 1135 | $12.49 | 44,306.0000 | 129,424,000 | 2.63% | 0.00% |
| Sept. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 6760 | $75.29 | 37,546.0000 | 129,424,000 | 15.26% | 0.01% |
| Sept. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 11271 | $12.07 | 43,171.0000 | 129,424,000 | 35.33% | 0.01% |
| Sept. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Option to Purchase Common Stock | 1135 | $0.00 | 812.0000 | 129,424,000 | 58.29% | 0.00% |
| Sept. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Option to Purchase Common Stock | 11271 | $0.00 | 0.0000 | 129,424,000 | 100.00% | 0.01% |
| Sept. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 13240 | $75.93 | 24,306.0000 | 129,424,000 | 35.26% | 0.01% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 6688 | $0.00 | 35,501.0000 | 129,424,000 | 23.21% | 0.01% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 6688 | $0.00 | 20,063.0000 | 129,424,000 | 25.00% | 0.01% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 3601 | $57.75 | 31,900.0000 | 129,424,000 | 10.14% | 0.00% |
| Feb. 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Restricted Stock Units | 21327 | $0.00 | 21,327.0000 | 129,424,000 | 9999.99% | 0.02% |
| Feb. 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Option to Purchase Common Stock | 22603 | $0.00 | 22,603.0000 | 129,424,000 | 9999.99% | 0.02% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 5093 | $0.00 | 29,095.0000 | 129,424,000 | 21.22% | 0.00% |
| Feb. 15, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 1254 | $0.00 | 16,734.0000 | 129,424,000 | 8.10% | 0.00% |
| Feb. 15, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 741 | $58.29 | 15,993.0000 | 129,424,000 | 4.43% | 0.00% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 17409 | $0.00 | 33,402.0000 | 129,424,000 | 108.85% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 9400 | $58.29 | 24,002.0000 | 129,424,000 | 28.14% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 2742 | $58.29 | 26,353.0000 | 129,424,000 | 9.42% | 0.00% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 5329 | $0.00 | 31,682.0000 | 129,424,000 | 20.22% | 0.00% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 2869 | $58.29 | 28,813.0000 | 129,424,000 | 9.06% | 0.00% |
| Feb. 15, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 1254 | $0.00 | 0.0000 | 129,424,000 | 100.00% | 0.00% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Performance Stock Units | 17409 | $0.00 | 0.0000 | 129,424,000 | 100.00% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 5093 | $0.00 | 5,093.0000 | 129,424,000 | 50.00% | 0.00% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 5329 | $0.00 | 10,658.0000 | 129,424,000 | 33.33% | 0.00% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Performance Stock Units | 6050 | $0.00 | 17,409.0000 | 129,424,000 | 53.26% | 0.00% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Performance Stock Units | 5221 | $0.00 | 8,184.0000 | 129,424,000 | 176.21% | 0.00% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Performance Stock Unit | 6935 | $0.00 | 6,935.0000 | 129,424,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Performance Stock Units | 28662 | $0.00 | 28,662.0000 | 129,424,000 | 9999.99% | 0.02% |
| July 22, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Option to Purchase Common Stock | 5000 | $0.00 | 0.0000 | 134,197,000 | 100.00% | 0.00% |
| July 22, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 992 | $54.25 | 15,480.0000 | 134,197,000 | 6.02% | 0.00% |
| July 22, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 4008 | $22.50 | 19,488.0000 | 134,197,000 | 25.89% | 0.00% |
| July 22, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 4008 | $53.85 | 15,480.0000 | 134,197,000 | 20.57% | 0.00% |
| July 22, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 992 | $22.50 | 16,472.0000 | 134,197,000 | 6.41% | 0.00% |
| June 26, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Option to Purchase Common Stock | 10000 | $0.00 | 25,000.0000 | 134,197,000 | 28.57% | 0.01% |
| June 28, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Option to Purchase Common Stock | 10000 | $0.00 | 5,000.0000 | 134,197,000 | 66.67% | 0.01% |
| June 27, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Option to Purchase Common Stock | 10000 | $0.00 | 15,000.0000 | 134,197,000 | 40.00% | 0.01% |
| June 28, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 10000 | $52.04 | 15,480.0000 | 134,197,000 | 39.25% | 0.01% |
| June 28, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 10000 | $22.50 | 25,480.0000 | 134,197,000 | 64.60% | 0.01% |
| June 27, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 10000 | $51.93 | 15,480.0000 | 134,197,000 | 39.25% | 0.01% |
| June 27, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 10000 | $22.50 | 25,480.0000 | 134,197,000 | 64.60% | 0.01% |
| June 26, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 10000 | $51.82 | 15,480.0000 | 134,197,000 | 39.25% | 0.01% |
| June 26, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 10000 | $22.50 | 25,480.0000 | 134,197,000 | 64.60% | 0.01% |
| Feb. 23, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Restricted Stock Units | 26751 | $0.00 | 26,751.0000 | 134,197,000 | 9999.99% | 0.02% |
| Feb. 23, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | A | Option to Purchase Common Stock | 27722 | $0.00 | 27,722.0000 | 134,197,000 | 9999.99% | 0.02% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 5329 | $0.00 | 15,987.0000 | 134,197,000 | 25.00% | 0.00% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 5329 | $0.00 | 18,344.0000 | 134,197,000 | 40.95% | 0.00% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 2737 | $36.10 | 13,015.0000 | 134,197,000 | 17.38% | 0.00% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 5093 | $0.00 | 15,752.0000 | 134,197,000 | 47.78% | 0.00% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 2864 | $36.10 | 15,480.0000 | 134,197,000 | 15.61% | 0.00% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 5093 | $0.00 | 10,186.0000 | 134,197,000 | 33.33% | 0.00% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 1254 | $0.00 | 1,254.0000 | 134,197,000 | 50.00% | 0.00% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 686 | $35.91 | 10,659.0000 | 134,197,000 | 6.05% | 0.00% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 1254 | $0.00 | 11,345.0000 | 134,197,000 | 12.43% | 0.00% |
| Feb. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Common Stock | 2502 | $0.00 | 11,568.0000 | 134,197,000 | 27.60% | 0.00% |
| Feb. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1477 | $35.49 | 10,091.0000 | 134,197,000 | 12.77% | 0.00% |
| Feb. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | M | Restricted Stock Units | 2502 | $0.00 | 0.0000 | 134,197,000 | 100.00% | 0.00% |